Moreover, only 47% of the tumours in the high-Ki67 category were shown to be Luminal B according to MS, which raises the question of whether a cut-off of 20% is too low to be able to identify Luminal B-like tumours and thereby identify patients with hormone receptor-positive tumours who might benefit from additional adjuvant chemotherapy. The gene discussed is MKI67; the disease is neoplasm.